Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose–response meta-analysis of 36,927 patients
Tóm tắt
Obesity is inconsistently related to biochemical recurrence (BCR) of prostate cancer (PCa) in different epidemiological studies. We conducted a systematic review and dose–response meta-analysis of published studies from MEDLINE and EMBASE in order to determine the relationship between body mass index (BMI) and BCR of PCa. We identified a total of 26 studies including 36,927 individuals. Pooled estimates of relative risk (RR) and confidence interval (CI) were computed, and dose–response meta-analysis was subsequently performed. Based on the random-effects approach, a 5 kg/m2 increase in BMI was associated with 16 % (RR 1.16, 95 % CI 1.08–1.24) higher risk of BCR for entire set of 26 studies. Significantly higher rates of BCR were also observed in radical prostatectomy series (RR 1.17, 95 % CI 1.07–1.28) and external beam radiation therapy series (RR 1.19, 95 % CI 1.10–1.28), while no significant correlation was observed in brachytherapy series (RR 0.91, 95 % CI 0.64–1.28). Different BCR outcomes came out for studies held in USA (RR 1.18, 95 % CI 1.10–1.28), Europe (RR 1.04 95 % CI 0.91–1.17) and Asia (RR 1.83 95 % CI 0.85–3.97), respectively. There was limited evidence of a nonlinear association between BMI and BCR, which showed a critical point of 33 in BMI. The findings from meta-analysis showed that excess BMI was positively correlated with BCR of PCa multifacetedly, indicating good weight control and detailed attention to treating obese patients might improve the prognosis of PCa.
Tài liệu tham khảo
Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378(9793):815–25.
Hajian-Tilaki KO, Gholizadehpasha AR, Bozorgzadeh S, Hajian-Tilaki E. Body mass index and waist circumference are predictor biomarkers of breast cancer risk in Iranian woman. Med Oncol. 2011;28(4):1296–301.
Puente Vazquez J, Grande Pulido E, Anton Aparicio LM. Cytokine and endocrine signaling in prostate cancer. Med Oncol. 2012;29(3):1956–63.
Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259–63.
Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4(4):486–501.
Mallah KN, DiBlasio CJ, Rhee AC, Scardino PT, Kattan MW. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer. 2005;103(10):2030–4.
Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer—a dose–response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665–71.
Magheli A, Rais-Bahrami S, Trock BJ, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 2008;72(6):1246–51.
Stroup SP, Cullen J, Auge BK, L’Esperance JO, Kang SK. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer. 2007;110(5):1003–9.
Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006;107(3):631–9.
Van Roermund JGH, Kok DEG, Wildhagen MF, et al. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU Int. 2009;104(3):321–5.
Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(5):1302–8.
Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose–response data. Stata J. 2006;6(1):40–57.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
Harbord RM, Harris RJ, Sterne J. Updated tests for small-study effects in meta-analyses. Stata J. 2009;9(2):197–210.
Narita S, Mitsuzuka K, Yoneyama T, et al. Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013;16(3):271–6.
Tomaszewski JJ, Chen Y-F, Bertolet M, Ristau BT, Woldemichael E, Nelson JB. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy. Urology. 2013;81(5):992–6.
Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA. Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013;16(1):62–6.
Campeggi A, Xylinas E, Ploussard G, et al. Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology. 2012;80(3):576–84.
Mucksavage P, Mitchell C, Kutikov A, Wein AJ, Torigian D, Malkowicz SB. Anthropometric differences in obese men with biochemical failure after radical retropubic prostatectomy. Urol Oncol. 2012;30(5):590–5.
Kok DEG, van Roermund JGH, Aben KK, et al. Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer. World J Urol. 2011;29(5):695–701.
Lee SE, Lee WK, Jeong MS, et al. Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU Int. 2011;107(8):1250–5.
Geinitz H, Thamm R, Mueller T, et al. Impact of body mass index on outcomes after conformal radiotherapy in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):16–22.
Sumitomo M, Asakuma J, Yoshii H, et al. Anterior perirectal fat tissue thickness is a strong predictor of recurrence after high-intensity focused ultrasound for prostate cancer. Int J Urol. 2010;17(9):776–82.
Lindner U, Lawrentschuk N, Abouassaly R, Fleshner NE, Trachtenberg J. Radical prostatectomy in obese patients: improved surgical outcomes in recent years. Int J Urol. 2010;17(8):727–32.
Ly D, Reddy CA, Klein EA, Ciezki JP. Association of body mass index with prostate cancer biochemical failure. J Urol. 2010;183(6):2193–9.
Van Roermund JGH, Hinnen KA, Battermann JJ, et al. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy. BJU Int. 2010;105(1):42–8.
Jayachandran J, Bañez LL, Aronson WJ, et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009;115(22):5263–71.
Pfitzenmaier J, Pritsch M, Haferkamp A, et al. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population? BJU Int. 2009;103(7):877–82.
Freedland SJ, Sun L, Kane CJ, et al. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008;102(8):969–74.
Hisasue S-I, Yanase M, Shindo T, et al. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy. Jpn J Clin Oncol. 2008;38(2):129–33.
Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol. 2007;178(5):1939–44.
Efstathiou JA, Chen M-H, Renshaw AA, Loffredo MJ, D’Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 2007;109(8):1493–8.
Siddiqui SA, Inman BA, Sengupta S, et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer. 2006;107(3):521–9.
Bassett WW, Cooperberg MR, Sadetsky N, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005;66(5):1060–5.
Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11(19):6889–94.
Chang SS, Duong DT, Wells N, Cole EE, Smith JA, Cookson MS. Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol. 2004;171(5):1861–5.
Wong JR, Gao Z, Merrick S, et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys. 2009;75(1):49–55.
Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173(6):1935–7.
Price RS, Cavazos DA, De Angel RE, et al. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012;15:135–43.